Paragon Gene Therapy, a unit of Catalent Biologics
801 West Baltimore Street
About Paragon Gene Therapy, a unit of Catalent Biologics
Paragon Gene Therapy is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon’s aim is to build strong client partnerships with the world’s best biotech and pharma companies, focusing on transformative technologies, including, gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics. Paragon's cGMP capabilities include fully-segregated mammalian, virus, and microbial facilities as well as small-batch aseptic fill-finish. In business over 25 years, Paragon’s scientists, engineers, quality systems personnel and project managers have the right experience to guide our clients through process development to GMP manufacturing for clinical trials and eventual commercial launch.
Paragon Gene Therapy offers employees a unique opportunity to not only develop their technical & functional skills but to also develop their understanding of how their work truly impacts the success of the organization. In the next few years, Paragon Gene Therapy, will triple in size allowing individual and team growth and the ability to evolve current practices. Opportunity to broaden each individual’s capability positively impacts the organizations ability to deliver stronger relationships to our clients furthering our goals as best in class CDMO. Our Scientists, Engineers, Quality Professionals and many business support teams have a rare opportunity to build an organization to rise up and meet the needs of pharmaceutical & biotechnology companies solving the world’s healthcare needs. Come be part of this amazing team!
7555 Harmans Road
Harmans, Maryland 21077
2017 ICE Awards Corporate Excellence Winner: Paragon Bioservices
57 articles with Paragon Gene Therapy, a unit of Catalent Biologics
Paragon Bioservices announces two key leadership promotions.
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
Seasoned Executive Gerard Fleury Joins the Company as Chief Financial Officer
The Company appoints Philip Wills, PhD, as CCO, John Conner as CMO, and William "Bill" Thomas, Jr., PhD, as CSO, and hires Randy Henrickson as VP of Manufacturing and Dermot McCaul as VP of Information Technology.
The new planned 150,000 square-foot facility, located in Maryland's Anne Arundel County, will facilitate Paragon's continued rapid growth.
Paragon Bioservices Release: NIAID Awards Company A Multiple Award IDIQ Contract Valued Up To $159 Million For Preclinical Drug Development Services
Paragon Bioservices Announces Promotion Of Peter Buzy To President And CEO And Election To Paragon's Board Of Directors
CEVEC And Paragon Bioservices Enter Into Comprehensive Collaboration To Roll Out CAP Technologies In North America
Paragon Bioservices Recognized As "Best Contract Manufacturing Organization" By World Vaccine Congress 2016
Paragon Bioservices Founder Marco Chacon Appointed By Governor Hogan To Maryland Life Sciences Advisory Board